Rocket Pharmaceuticals, Inc. (RCKT) Return on equity 2016–2025
Rocket Pharmaceuticals, Inc. (RCKT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-80.5%FY2025 · since FY2016: -90.5% → -80.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -80.5% | -24.6 pp |
| FY2024 | -55.9% | -6.0 pp |
| FY2023 | -49.9% | -4.6 pp |
| FY2022 | -45.3% | -8.1 pp |
| FY2021 | -37.2% | -9.4 pp |
| FY2020 | -27.7% | -2.6 pp |
| FY2019 | -25.1% | +13.3 pp |
| FY2018 | -38.4% | +87.8 pp |
| FY2017 | -126.2% | -35.7 pp |
| FY2016 | -90.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RCKT financial trends
RCKT RevenueRCKT Net incomeRCKT Net marginRCKT Gross profitRCKT Gross marginRCKT Operating incomeRCKT Operating marginRCKT Operating cash flowRCKT Free cash flowRCKT Capital expendituresRCKT Stock buybacksRCKT Dividends paidRCKT Total assetsRCKT Total liabilitiesRCKT Shareholders’ equityRCKT overview →